(Q35053929)

6 August 2017

1 reference

title

Prostate carcinoma: defining therapeutic objectives and improving overall outcomes (English)

1 reference

6 August 2017

1 reference

Howard I Scher

1

1 reference

PubMed ID

12548573

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

97

1 reference

6 August 2017

758-771

1 reference

6 August 2017

3 Suppl

1 reference

6 August 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A catalog of prostate cancer nomograms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Clinical review 134: The endocrinology of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Defining the role of antiandrogens in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Patients' choice of treatment in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Xenografts of primary human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Mechanisms governing bone metastasis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Detectable tumor cells in the blood and bone marrow: smoke or fire?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Identification of bone marrow micrometastases in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Surrogate end points in clinical trials: are we being misled?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

The phase II/III transition. Toward the proof of efficacy in cancer clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Novel strategies and therapeutics for the treatment of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11151

7 January 2021

Identifiers

DOI

10.1002/CNCR.11151

1 reference

6 August 2017

1 reference

PubMed ID

12548573